组氨酸-色氨酸-酮戊二酸液用于供体心脏保存安全可行
该回顾性研究基于UNOS数据库(2004-2016)比较本中心使用HTK液保存供心与其他中心的心脏移植结局。经1:3倾向性匹配后,本中心HTK队列供者心脏骤停比例更高、骤停时间更长,但严重原发性移植物功能障碍(PGD)需机械支持率低,总体生存率与全国平均水平无显著差异。
要点
- HTK液保存供心后严重PGD需机械支持率仅4.2%。
- HTK组供者心脏骤停比例更高但总体生存与全国无差异。
- HTK液用于供心保存有效且安全。
核心结论
- 使用HTK液保存供体心脏与低严重PGD率相关,总体生存率与使用多种保存液的其他中心无显著差异。
研究设计与样本
- 回顾性分析UNOS数据库(2004-2016),比较本中心HTK保存供心移植结局与其他全国中心,采用1:3倾向性匹配调整术前受者变量。
主要发现
- 匹配后本中心HTK队列(n=360)与UNOS队列(n=1080)术前变量无差异,供者年龄、性别、大小比、LVEF及缺血时间相似。
- HTK组供者心脏骤停比例更高(26.3% vs 6.1%,P < .001),心脏骤停时间更长(22.1 ± 16.0 vs 17.2 ± 14.0分钟,P = .052)。
- HTK组需机械支持的PGD率为4.2%(n=1),术后机械支持包括ECMO 9例(60.0%)、IABP 4例(26.7%)、RVAD 3例(20%)、BiVAD 3例(20%)。
- 本中心总体生存率与全国平均水平相似(P = .649);HTK组1、5、10年生存率分别为92.2%、81.3%、70.8%,UNOS人群分别为91.6%、80.3%、62.0%。
临床怎么用
- HTK液可作为供体心脏保存的有效选择,尤其供者心脏骤停比例较高时严重PGD率仍低。
局限性
- 回顾性研究设计,非随机比较,可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various solutions are used for donor heart preservation. We examined the outcomes in our heart transplant population where histidine-tryptophan-ketoglutarate (HTK) solution has been used for heart preservation since 2004. METHODS: This was a retrospective review of the United Network for Organ Sharing (UNOS) database (2004-2016) comparing our heart transplant outcomes with other national centers. Propensity matching in a 1:3 ratio was performed to adjust for preoperative recipient variables. RESULTS: After propensity matching comparing UNOS outcomes (n = 1080) with our institutional data (n = 360), there was no difference in matched preoperative variables. Donor hearts were similar for donor age, sex, donor-to-recipient size ratio, LVEF, and ischemic time. Our HTK cohort had a larger proportion with donor cardiac arrest (26.3% vs 6.1%, P < .001) and longer cardiac arrest duration (22.1 ± 16.0 vs 17.2 ± 14.0 minutes, P = .052). Our primary graft dysfunction (PGD) rate requiring mechanical support was 4.2% (n = 1). Postoperative mechanical support use for PGD included extracorporeal membrane oxygenation in 9 (60.0%), intraaortic balloon pump in 4 (26.7%), right ventricular assist device in 3 (20%), and biventricular assist device in 3 (20%). Overall survival at our institution was similar to the national average (P = .649). Survival at 1, 5, and 10 years with HTK was 92.2%, 81.3%, and 70.8%, and for the UNOS population was 91.6%, 80.3%, and 62.0%, respectively. CONCLUSIONS: Use of HTK solution for donor hearts was associated with a low rate of severe PGD. Overall survival was not significantly different from other institutions using a variety of preservation solutions in the UNOS database during the same period. HTK solution is efficacious for preservation of donor hearts.
引用
- Mokbel M, Zamani H, Lei I, et al. Histidine-Tryptophan-Ketoglutarate Solution for Donor Heart Preservation Is Safe for Transplantation. Ann Thorac Surg. 2019. PMID: 31470011. doi:10.1016/j.athoracsur.2019.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。